JP2015527374A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015527374A5 JP2015527374A5 JP2015530072A JP2015530072A JP2015527374A5 JP 2015527374 A5 JP2015527374 A5 JP 2015527374A5 JP 2015530072 A JP2015530072 A JP 2015530072A JP 2015530072 A JP2015530072 A JP 2015530072A JP 2015527374 A5 JP2015527374 A5 JP 2015527374A5
- Authority
- JP
- Japan
- Prior art keywords
- melanoma
- pharmaceutical composition
- composition according
- dabrafenib
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010025650 Malignant melanoma Diseases 0.000 claims 8
- 201000001441 melanoma Diseases 0.000 claims 8
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- BFSMGDJOXZAERB-UHFFFAOYSA-N Dabrafenib Chemical compound S1C(C(C)(C)C)=NC(C=2C(=C(NS(=O)(=O)C=3C(=CC=CC=3F)F)C=CC=2)F)=C1C1=CC=NC(N)=N1 BFSMGDJOXZAERB-UHFFFAOYSA-N 0.000 claims 4
- 229960002465 dabrafenib Drugs 0.000 claims 4
- 102100004328 BRAF Human genes 0.000 claims 3
- 101700004551 BRAF Proteins 0.000 claims 3
- 238000003745 diagnosis Methods 0.000 claims 3
- 230000035772 mutation Effects 0.000 claims 3
- LIRYPHYGHXZJBZ-UHFFFAOYSA-N Trametinib Chemical compound CC(=O)NC1=CC=CC(N2C(N(C3CC3)C(=O)C3=C(NC=4C(=CC(I)=CC=4)F)N(C)C(=O)C(C)=C32)=O)=C1 LIRYPHYGHXZJBZ-UHFFFAOYSA-N 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 230000004083 survival Effects 0.000 claims 2
- 229960004066 trametinib Drugs 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 238000009098 adjuvant therapy Methods 0.000 claims 1
- 238000002271 resection Methods 0.000 claims 1
Claims (8)
- 黒色腫の従前の診断を有し、該黒色腫が切除されている患者にアジュバント治療を提供するための、治療上有効用量のダブラフェニブおよびトラメチニブを含む、医薬組成物。
- ダブラフェニブが1日2回150mgの量で投与される、請求項1に記載の医薬組成物。
- トラメチニブが1日1回2mgの量で投与される、請求項1に記載の医薬組成物。
- 患者がステージIII黒色腫の従前の診断を有し、該ステージIII黒色腫が切除されている、請求項1に記載の医薬組成物。
- 患者がBRAF V600変異陽性黒色腫の従前の診断を有し、該BRAF V600変異陽性黒色腫が切除されている、請求項1に記載の医薬組成物。
- 黒色腫の切除後の患者の無再発生存期間(RFS)を増加させるための、ダブラフェニブとトラメチニブを含んでなる、医薬組成物。
- 前記黒色腫がBRAF V600変異陽性である、請求項6に記載の医薬組成物。
- 黒色腫の切除後の患者における無再発生存期間(RFS)の増加において使用するための、ダブラフェニブとトラメチニブの組み合わせを含む組成物。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261696375P | 2012-09-04 | 2012-09-04 | |
| US61/696,375 | 2012-09-04 | ||
| PCT/US2013/057432 WO2014039375A1 (en) | 2012-09-04 | 2013-08-30 | Method of adjuvant cancer treatment |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017216933A Division JP6511117B2 (ja) | 2012-09-04 | 2017-11-10 | アジュバント癌治療の方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015527374A JP2015527374A (ja) | 2015-09-17 |
| JP2015527374A5 true JP2015527374A5 (ja) | 2016-10-06 |
Family
ID=50237545
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015530072A Pending JP2015527374A (ja) | 2012-09-04 | 2013-08-30 | アジュバント癌治療の方法 |
| JP2017216933A Active JP6511117B2 (ja) | 2012-09-04 | 2017-11-10 | アジュバント癌治療の方法 |
| JP2019072361A Active JP6684941B2 (ja) | 2012-09-04 | 2019-04-05 | アジュバント癌治療の方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017216933A Active JP6511117B2 (ja) | 2012-09-04 | 2017-11-10 | アジュバント癌治療の方法 |
| JP2019072361A Active JP6684941B2 (ja) | 2012-09-04 | 2019-04-05 | アジュバント癌治療の方法 |
Country Status (21)
| Country | Link |
|---|---|
| US (6) | US20150216868A1 (ja) |
| EP (2) | EP2892535B1 (ja) |
| JP (3) | JP2015527374A (ja) |
| KR (1) | KR102134585B1 (ja) |
| CN (2) | CN104582706A (ja) |
| AU (2) | AU2013313050A1 (ja) |
| BR (1) | BR112015004578A2 (ja) |
| CA (1) | CA2882437C (ja) |
| CY (1) | CY1124812T1 (ja) |
| DK (1) | DK2892535T3 (ja) |
| ES (1) | ES2900825T3 (ja) |
| HK (1) | HK1206642A1 (ja) |
| HR (1) | HRP20211817T1 (ja) |
| HU (1) | HUE056646T2 (ja) |
| IN (1) | IN2015KN00449A (ja) |
| LT (1) | LT2892535T (ja) |
| PL (1) | PL2892535T3 (ja) |
| PT (1) | PT2892535T (ja) |
| RU (1) | RU2640180C2 (ja) |
| SI (1) | SI2892535T1 (ja) |
| WO (1) | WO2014039375A1 (ja) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IN2015KN00449A (ja) | 2012-09-04 | 2015-07-17 | Glaxosmithkline Llc | |
| EP3524694B1 (en) | 2013-12-28 | 2020-07-15 | Guardant Health, Inc. | Methods and systems for detecting genetic variants |
| FI3618875T3 (fi) * | 2017-05-02 | 2023-07-04 | Novartis Ag | Raf-inhibiittoria ja trametinibia käsittävä yhdistelmähoito |
| WO2019204399A1 (en) * | 2018-04-17 | 2019-10-24 | The University Of Chicago | Methods and compositions for treating cancer |
| CN109106893B (zh) * | 2018-11-12 | 2021-04-20 | 上海市中西医结合医院 | 一种调节肠道屏障功能的中药复方制剂及其制备方法 |
| WO2023105286A1 (en) | 2021-12-06 | 2023-06-15 | My Personal Therapeutics Ltd | A combination treatment for cancer |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2364596C2 (ru) | 2004-06-11 | 2009-08-20 | Джапан Тобакко Инк. | ПРОИЗВОДНЫЕ 5-АМИНО-2,4,7-ТРИОКСО-3,4,7,8-ТЕТРАГИДРО-2Н-ПИРИДО[2,3-d] ПИРИМИДИНА, ОБЛАДАЮЩИЕ ПРОТИВООПУХОЛЕВОЙ АКТИВНОСТЬЮ |
| CN105288630A (zh) * | 2005-02-18 | 2016-02-03 | 阿布拉科斯生物科学有限公司 | 治疗剂的组合和给予方式以及联合治疗 |
| UA103319C2 (en) | 2008-05-06 | 2013-10-10 | Глаксосмитклайн Ллк | Thiazole- and oxazole-benzene sulfonamide compounds |
| DK3560498T3 (da) * | 2009-10-16 | 2022-11-14 | Novartis Ag | Kombination, der omfatter en mek-hæmmer og en b-raf-hæmmer |
| US20130004481A1 (en) * | 2011-01-12 | 2013-01-03 | Boehringer Ingelheim International Gmbh | Anticancer therapy |
| IN2015KN00449A (ja) | 2012-09-04 | 2015-07-17 | Glaxosmithkline Llc |
-
2013
- 2013-08-30 IN IN449KON2015 patent/IN2015KN00449A/en unknown
- 2013-08-30 CN CN201380046144.4A patent/CN104582706A/zh active Pending
- 2013-08-30 RU RU2015105821A patent/RU2640180C2/ru active
- 2013-08-30 CN CN201710300645.0A patent/CN107308164A/zh active Pending
- 2013-08-30 WO PCT/US2013/057432 patent/WO2014039375A1/en active Application Filing
- 2013-08-30 PL PL13835019T patent/PL2892535T3/pl unknown
- 2013-08-30 HR HRP20211817TT patent/HRP20211817T1/hr unknown
- 2013-08-30 BR BR112015004578A patent/BR112015004578A2/pt not_active IP Right Cessation
- 2013-08-30 PT PT138350194T patent/PT2892535T/pt unknown
- 2013-08-30 AU AU2013313050A patent/AU2013313050A1/en not_active Abandoned
- 2013-08-30 LT LTEPPCT/US2013/057432T patent/LT2892535T/lt unknown
- 2013-08-30 SI SI201331951T patent/SI2892535T1/sl unknown
- 2013-08-30 JP JP2015530072A patent/JP2015527374A/ja active Pending
- 2013-08-30 EP EP13835019.4A patent/EP2892535B1/en active Active
- 2013-08-30 CA CA2882437A patent/CA2882437C/en active Active
- 2013-08-30 US US14/422,182 patent/US20150216868A1/en not_active Abandoned
- 2013-08-30 KR KR1020157008387A patent/KR102134585B1/ko active IP Right Grant
- 2013-08-30 DK DK13835019.4T patent/DK2892535T3/da active
- 2013-08-30 ES ES13835019T patent/ES2900825T3/es active Active
- 2013-08-30 HU HUE13835019A patent/HUE056646T2/hu unknown
- 2013-08-30 EP EP21190550.0A patent/EP3981408A1/en active Pending
-
2015
- 2015-08-03 HK HK15107423.5A patent/HK1206642A1/xx unknown
-
2016
- 2016-10-13 AU AU2016244279A patent/AU2016244279B2/en active Active
-
2017
- 2017-04-05 US US15/479,663 patent/US20170202842A1/en not_active Abandoned
- 2017-11-10 JP JP2017216933A patent/JP6511117B2/ja active Active
-
2018
- 2018-08-07 US US16/056,702 patent/US20180338979A1/en not_active Abandoned
-
2019
- 2019-04-05 JP JP2019072361A patent/JP6684941B2/ja active Active
- 2019-10-28 US US16/664,978 patent/US10869869B2/en active Active
-
2020
- 2020-11-11 US US17/095,200 patent/US20210060021A1/en not_active Abandoned
-
2021
- 2021-12-15 CY CY20211101105T patent/CY1124812T1/el unknown
-
2022
- 2022-12-07 US US18/062,764 patent/US20230330091A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015527374A5 (ja) | ||
| CY1125292T1 (el) | Παραγωγα 6,7,8,9-tetpaϋδpo-3h-πypazoλo[4,3-f iσοκινολινης χρησιμα στη θεραπευτικη αντιμετωπιση του καρκινου | |
| JP2019503365A5 (ja) | ||
| JP2013509429A5 (ja) | ||
| JP2015536964A5 (ja) | ||
| JP2015523397A5 (ja) | ||
| CL2018001371A1 (es) | Uso de un inhibidor de b-raf y de un inhibidor de mek 1/2 para el tratamiento de un paciente que padece melanoma (divisional solicitud 201502807) | |
| PH12014502447A1 (en) | Use of high dose laquinimod for treating multiple sclerosis | |
| AR082091A1 (es) | Composiciones farmaceuticas que comprenden pioglitazona y linagliptina y procedimiento de preparacion | |
| EA201100971A1 (ru) | Производные пиримидининдола для лечения злокачественного новообразования | |
| RU2015121367A (ru) | Фармацевтическая комбинация, содержащая ингибитор b-raf и ингибитор деацетилазы гистонов, и ее применение при лечении пролиферативных заболеваний | |
| EA200901155A1 (ru) | Модуляторы фармакокинетических свойств терапевтических препаратов (варианты) и их использование в терапии | |
| JP2011519846A5 (ja) | ||
| AR078588A1 (es) | Combinaciones de un inhibidor de pi3k y un inhibidor de mek | |
| JP2015511609A5 (ja) | ||
| JP2015528491A5 (ja) | ||
| ECSP12011703A (es) | Composiciones farmacéuticas para el tratamiento del cáncer y otras enfermedades o trastornos | |
| JP2015502926A5 (ja) | ||
| JP2014050390A5 (ja) | ||
| CY1121166T1 (el) | Ενωσεις για τη θεραπεια παχυσαρκιας και μεθοδοι χρησης αυτων | |
| JP2015507020A5 (ja) | ||
| JP2013541583A5 (ja) | ||
| JP2015537009A5 (ja) | ||
| JP2014512355A5 (ja) | ||
| RU2015105821A (ru) | Способ адъювантного лечения рака |